Cargando…
Tofacitinib to Treat Severe Acute Refractory Colitis in a Teenager: Case Report and Review of the Literature
Acute severe colitis (ASC) may occur within 3 months of ulcerative colitis diagnosis in 9%–15% of children and the rate of colectomy is up to 40%–50% within 5 years after an ASC. The aim of this publication is to present recent and relevant data on the success of medical treatment with tofacitinib i...
Autores principales: | Girard, Chloé, Dirks, Martha, Deslandres, Colette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158282/ https://www.ncbi.nlm.nih.gov/pubmed/37168636 http://dx.doi.org/10.1097/PG9.0000000000000241 |
Ejemplares similares
-
Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022) -
Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
por: Malakar, Sayan, et al.
Publicado: (2023) -
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021) -
Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature
por: Alajmi, Refaa, et al.
Publicado: (2021) -
Japanese pediatric patient with refractory steroid-resistant ulcerative colitis successfully treated with Tofacitinib: A case report
por: Kakiuchi, Toshihiko, et al.
Publicado: (2022)